Abstract. Matrix metalloproteinase-7 (MMP-7), MMP-9, MMP-13, and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) are considered to have important roles in the invasiveness and outcomes of colorectal cancer (CRC). This study examined the clinicopathological significance of the relative expression of these genes in patients with colorectal cancer, especially as related to liver metastasis. The study analysed surgical specimens of cancer tissue and adjacent normal mucosa obtained from 202 patients with untreated colorectal cancer. MMP-7, MMP-9, MMP-13, TIMP-1, and β-actin mRNA of cancer tissue and adjacent normal mucosa were measured by quantitative real-time, reverse-transcriptase polymerase chain reaction. Expression levels of MMP-7, MMP-9, MMP-13 and TIMP-1 were higher in cancer tissue than in adjacent normal mucosa. On analysis of the relations between gene expression and clinicopathological factors, MMP-13 expression was found to correlate with liver metastasis. Moreover, MMP-13 expression levels were higher in tumour tissue with liver metastasis than in that without liver metastasis. It is concluded that MMP-13 gene expression is a useful predictor of liver metastasis in patients with CRC.

Colorectal cancer (CRC), one of the most prevalent cancers worldwide (1), is the second leading cause of cancer-related mortality in developed countries (2). Tumour invasion and metastasis involve degradation of different components of the extracellular matrix, catalysed by proteolytic enzymes such as matrix metalloproteinases (MMPs) (3). Several MMPs have been shown to be associated with tumour stage and outcomes in CRC (4). Degradation of type IV collagen correlates with metastatic potential (5, 6). Type IV collagen is particularly abundant in basement membranes and is degraded by not only MMP-2 and MMP-9, but also by MMP-3, MMP-7, MMP-10, MMP-11, MMP-13, MMP-26. The MMP family can cleave several extracellular matrix components during tumour invasion (7, 8). Expression of MMP-7 is elevated in several types of malignancy (9-11). MMP-9 can degrade denatured collagen, as well as types IV, V, VII, IX, and X collagen. MMP-9 has been implicated in the progression, invasion, and metastasis of colorectal cancer in animal models and patients (12). Human collagenase-3 (MMP-13), which represents the third member of the collagenase subfamily, has been identified in human breast carcinomas and osteoarthritic cartilage (13, 14). MMP-13 is detected in several types of malignancy (15-21). MMP-13 has been shown to correlate with poor outcomes in different types of cancer (15, 22-28). In addition to acting as an MMP, MMP-13 also has a central role in the MMP activation cascade (15). MMP-13 is activated by MMP-2, MMP-3 and MT-MMP and then activates MMP-2 and MMP-9 (29-32). The activities of MMPs are regulated not only at the gene expression level, but also at the protein level by inhibitors, such as the family of tissue inhibitors of metalloproteinases (TIMPs). Recently, TIMP-1 has been demonstrated to have various functions such as inhibition of apoptosis, stimulation of growth and promotion of angiogenesis (33-39).

This study evaluated the relations of expression levels of MMP-7, MMP-9, MMP-13 and TIMP-1 to clinicopathological variables, especially liver metastasis, in patients with CRC.
Materials and Methods

Patients and samples. Analysis was performed on surgical specimens of cancer tissue and adjacent normal mucosa obtained from 202 patients with untreated CRC. The patients underwent surgery at Yokohama City University Medical Center, Gastroenterological Center and at Kanagawa Cancer Center, Department of Gastrointestinal Surgery between 2002 and 2006. Informed consent was obtained from all patients. The ethics committees of Yokohama City University Medical Center and Kanagawa Cancer Center approved the protocol before initiation of the study. All tissue samples were embedded in OCT compound (Sakura Finetech Co., Ltd, Tokyo) and immediately stored at –80°C until use. No patient had any other malignancies. The histopathological features of specimens stained with hematoxylin and eosin were examined, and sections that consisted of >80% cancer cells were used to prepare total RNA.

Quantitative real-time, reverse-transcription polymerase chain reaction (PCR). Total RNA isolated from CRC and adjacent normal mucosa was prepared with the use of Trizol (Gibco, Life Tech, Gaithersburg, MD, USA). Complementary DNA (cDNA) was synthesised from 2 μg of total RNA with an iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). After synthesis, the cDNA was diluted 1:4 with water and stored at –20°C until use. Quantitative real-time PCR was performed with an iQSYBR-Green Supermix (Bio-Rad Laboratories). PCR reactions were carried out in a total volume of 15 μl, containing cDNA derived from 75 ng of mRNA, 0.27 μM of each primer, 7.5 μl of iQ SYBR-Green Supermix containing dATP, dCTP, dGTP, and dTTP at concentrations of 400 μM each, and 50U/ml of iTag DNA polymerase. The PCR consisted of 10 min at 94°C, annealing for 30 sec at an appropriate temperature (Table I), and a primer extension for 1 min at 72°C, followed by 10 min at 72°C. The PCR primer sequences of MMP-7, MMP-9, MMP-13, TIMP-1 and β-actin, used as an internal control, are shown in Table I.

Statistical analysis. Gene expression levels of CRC were compared with those of adjacent normal mucosa by the Wilcoxon test. Relations between gene expression and potential explanatory variables, including age, gender, tumour size, histological type, depth of invasion, location, lymphatic invasion, lymph node metastasis, venous invasion and liver metastasis, were evaluated with the χ² test. Associations between variables were assessed using the Mann-Whitney U test. All statistical analyses were performed using the SPSS II program, version 11.0.1J for Windows (SPSS Inc., Chicago, IL, USA). Two-sided p values were calculated, and a difference was considered statistically significant at p<0.05. Data are expressed as median±SD.

Results

Comparison of MMP-7, MMP-9, MMP-13 and TIMP-1 gene expression between CRC tissue and adjacent normal mucosa. Gene expression levels of MMP-7, MMP-9, MMP-13 and TIMP-1 were significantly higher in cancer tissue than in adjacent normal mucosa (MMP-7: 4.10±392.80 versus 0.05±4.65, p<0.001; MMP-9: 0.59±4.54 versus 0.11±5.78, p<0.001; MMP-13: 7.27±34.02 versus 2.20±11.23, p<0.001; and TIMP-1: 6.12±12.60 versus 0.66±2.53, p<0.001) (Figure 1).

Relations of clinicopathological features to MMP-7, MMP-9, MMP-13 and TIMP-1 gene expression levels in CRC tissue. Expression levels of each gene were categorised as low or high according to their respective median values. Relations between the expression levels of each gene and clinicopathological features were then examined. MMP-7, MMP-9 and TIMP-1 gene expression levels were unrelated to age, gender, tumour size, histological type, depth of invasion, tumour location, lymphatic invasion, lymph node metastasis, venous invasion and liver metastasis. High expression of the MMP-13 gene was significantly related to liver metastasis (40/101 versus 22/101, p=0.009), but was unrelated to age, gender, tumour size, histological type, depth of invasion, tumour location, lymphatic invasion, lymph node metastasis and venous invasion (Table II).

Comparison of MMP-7, MMP-9, MMP-13 and TIMP-1 gene expression levels in CRC tissue according to the presence or absence of liver metastasis. Only MMP-13 gene expression differed significantly according to the presence or absence of liver metastasis (8.89±59.16 versus 6.67±9.70, p=0.015).
Table II. Relations between the expression of MMP-7, MMP-9, MMP-13 and TIMP-1 genes and clinicopathological features.

<table>
<thead>
<tr>
<th>Variable/category</th>
<th>MMP-7 Expression</th>
<th>MMP-9 Expression</th>
<th>MMP-13 Expression</th>
<th>TIMP-1 Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (n=101)</td>
<td>High (n=101)</td>
<td>Low (n=101)</td>
<td>High (n=101)</td>
</tr>
<tr>
<td></td>
<td>p-Value</td>
<td>Low (n=101)</td>
<td>High (n=101)</td>
<td>Low (n=101)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p-Value</td>
<td>Low (n=101)</td>
<td>High (n=101)</td>
</tr>
<tr>
<td>Age</td>
<td>66.8±10.7</td>
<td>64.6±10.9</td>
<td>0.155</td>
<td>66.1±10.7</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>62 48</td>
<td>0.066</td>
<td>56 54</td>
<td>0.888</td>
</tr>
<tr>
<td>Female</td>
<td>39 53</td>
<td></td>
<td>45 47</td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 cm</td>
<td>55 57</td>
<td>0.887</td>
<td>58 54</td>
<td>0.671</td>
</tr>
<tr>
<td>≥5 cm</td>
<td>46 44</td>
<td></td>
<td>43 47</td>
<td></td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>32 27</td>
<td>0.605</td>
<td>28 31</td>
<td>0.563</td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>57 58</td>
<td></td>
<td>61 54</td>
<td></td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>12 16</td>
<td></td>
<td>12 16</td>
<td></td>
</tr>
<tr>
<td>Depth of invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1/T2</td>
<td>55 55</td>
<td>1.000</td>
<td>59 51</td>
<td>0.323</td>
</tr>
<tr>
<td>T3/T4</td>
<td>46 46</td>
<td></td>
<td>42 50</td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>57 52</td>
<td>0.572</td>
<td>59 50</td>
<td>0.259</td>
</tr>
<tr>
<td>Rectum</td>
<td>44 49</td>
<td></td>
<td>42 51</td>
<td></td>
</tr>
<tr>
<td>Lymphatic invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>66 66</td>
<td>1.000</td>
<td>68 64</td>
<td>0.658</td>
</tr>
<tr>
<td>Present</td>
<td>35 35</td>
<td></td>
<td>33 37</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>44 49</td>
<td>0.572</td>
<td>42 51</td>
<td>0.259</td>
</tr>
<tr>
<td>Present</td>
<td>57 52</td>
<td></td>
<td>59 50</td>
<td></td>
</tr>
<tr>
<td>Venous invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>44 49</td>
<td>0.572</td>
<td>42 51</td>
<td>0.259</td>
</tr>
<tr>
<td>Present</td>
<td>57 52</td>
<td></td>
<td>59 50</td>
<td></td>
</tr>
<tr>
<td>Liver metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>68 72</td>
<td>0.647</td>
<td>70 70</td>
<td>1.000</td>
</tr>
<tr>
<td>Present</td>
<td>33 29</td>
<td></td>
<td>31 31</td>
<td></td>
</tr>
</tbody>
</table>
The expression levels of the other genes did not differ significantly according to the presence or absence of liver metastasis (Figure 2).

Discussion

MMPs play a key role in the development and progression of human malignancies (3, 40, 41). MMP-7, MMP-9 and MMP-13 correlate with tumour invasion, angiogenesis, metastasis and progression in CRC (15, 23, 42-47). Several previous studies have compared MMP-7, MMP-9, MMP-13 and TIMP-1 mRNA expression levels between CRC tissue and adjacent normal mucosa. Miyata et al. (48) reported that the expression of MMP-7 in tumour cells is significantly higher than that in normal cells. Pesta et al. (49) showed that the levels of MMP-7 and TIMP-1 mRNA differ significantly between normal colorectal tissue and tumour tissue. Kim et al. (50) and Lubbe et al. (51) found that MMP-9 gene expression levels are higher in CRC than in adjacent normal mucosa. Leeman et al. (15) reported that MMP-13 activity is significantly higher in tumour tissue than in normal colonic mucosa and that such activity is localised to the cytoplasm of tumour cells. Offenberg et al. (52) demonstrated that TIMP-1 is upregulated in CRC tissue as compared with normal tissue. Asano et al. (53) reported that the expression of MMP-7 and MMP-9 differs significantly between cancer tissue and normal mucosa, whereas the expression of MMP-13 and TIMP-1 does not. Asano et al. (53) compared the expression levels of these genes between 112 specimens of CRC and 20 specimens of normal mucosa. In the present study, gene expression levels were compared between 202 specimens of cancerous mucosa and 202 specimens of adjacent normal mucosa. The study showed that the gene expression levels of MMP-7, MMP-9, MMP-13 and TIMP-1 are higher in CRC tissue than in adjacent normal mucosa.

The present study examined whether expression levels of the MMP-7, MMP-9, MMP-13 and TIMP-1 genes are related to clinicopathological features. Nosho et al. (54) found that MMP-7 gene expression correlates with tumour size, location and histopathological type in early CRC. Miyata et al. (48)
reported that MMP-7 expression in cancer cells correlates with an advanced pathological tumour stage. Ogata et al. (55) showed that MMP-9 expression is related to lymph node metastasis and severe venous invasion. Leeman et al. (15) demonstrated that MMP-13 activity is associated with poor survival in CRC. Pesta et al. (49) reported no significant correlation between TIMP-1 expression and clinicopathological features. In the present study, MMP-7, MMP-9 and TIMP-1 expression, were unrelated to clinicopathological features. MMP-13 expression was significantly associated with liver metastasis, but not with any other clinicopathological feature.

A number of previous studies have examined whether enzymatic expression levels of MMP-7, MMP-9, MMP-13 in CRC tissue correlate with the presence or absence of liver metastasis. Ogawa et al. (56) showed that the expression of MMP-7 is associated liver metastasis. Previous studies reported that MMP-7 plays an important role in the development of liver metastasis from human CRC (45-47). Zeng and Guillem (57) suggested that activation of MMP-9 may be a pivotal event in the formation of colorectal liver metastasis. Matsuyama et al. (58) reported that active-form MMP-9 is more strongly expressed in colon carcinomas from patients with liver metastasis than in those from patients without liver metastasis. Kopitz et al. (59) showed that TIMP-1 promotes liver metastasis. The present study examined the relations of gene expression levels of MMP-7, MMP-9, MMP-13 and TIMP-1 to clinicopathological factors, including liver metastasis in patients with CRC. It was found that MMP-7, MMP-9 and TIMP-1 expressions were not related to liver metastasis in CRC. No previous study has examined whether MMP-13 expression is related to liver metastasis in CRC. In this study, only MMP-13 gene expression differed significantly according to the presence or absence of liver metastasis. These results showed that a higher MMP-13 expression level is associated with a higher rate of liver metastasis. This finding suggests that MMP-13 plays an important role in liver metastasis in patients with CRC. It is concluded that MMP-13 gene expression may be a useful predictor of liver metastasis from CRC.

Figure 2. Comparison of expression levels of MMP-7, MMP-9, MMP-13 and TIMP-1 genes in CRC tissue according to the presence (H+) or absence (H–) of liver metastasis. The expression level of MMP-13 gene was higher in the presence than in the absence of liver metastasis (p=0.015). p-Values were calculated by the Mann-Whitney U test.
References


Received May 6, 2010
Revised June 4, 2010
Accepted June 9, 2010